CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event. About ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at ...

And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...

Let's find out. Intellia Therapeutics focuses on developing therapies for rare diseases. The company has two products in ...

Groups of districts already working on escaping the factory model applied for grant money to work on innovative high school options.

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a natural defense system in bacteria that scientists have adapted into a powerful gene-editing tool. This ...

Vertex Pharmaceuticals (VRTX) is rapidly closing the market capitalization gap with pharmaceutical behemoth Pfizer (PFE), leveraging a robust growth trajectory and a diversified pipeline that ...

According to Bloomberg News, Vinay Prasad, who oversees gene therapies at the FDA, said the plans will be published in early November. He foresees the approach sparking curiosity for the next wave of ...